Cara Therapeutics (CARA) Misses Q3 EPS by 7c

Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.13 million versus the consensus estimate of $180 thousand.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
• UBS says bull market has further to run